Chiauranib

西奥罗尼

Report date: 2026/05/22 20:01:29
NME

Base Information

Drug NameChiauranib
Drug Alias NameIbcasertibAurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitorCS-2164CS2164
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase Aurora-B inhibitorsVascular endothelial growth factor receptor antagonistsPlatelet-derived growth factor receptor inhibitors +[5] 
TargetsSerine/threonine-protein kinase Aurora-BVascular endothelial growth factor receptorPlatelet-derived growth factor receptor +[5] 
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaOvarian Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShenzhen Chipscreen Biosciences Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAkeso Pharmaceuticals IncSun Yat-Sen UniversityChengdu Chipscreen Pharmaceutical Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung CarcinomaOvarian NeoplasmsCarcinoma, Pancreatic Ductal +[5] 
Inactive IndicationsSolid tumoursTriple Negative Breast NeoplasmsCarcinoma, Hepatocellular +[4] 

Other Information

ATC CodeN/A
Related LinksDrugBank